Evoke Pharma, Inc.
EVOK
$5.49
$0.0761.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.01% | 89.89% | 97.84% | 100.35% | 110.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.01% | 89.89% | 97.84% | 100.35% | 110.79% |
| Cost of Revenue | 89.47% | 25.35% | 76.57% | -10.81% | -41.25% |
| Gross Profit | 69.41% | 92.57% | 98.70% | 109.67% | 129.32% |
| SG&A Expenses | 30.80% | 29.71% | 23.33% | 28.50% | 28.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.97% | 28.84% | 22.53% | 25.63% | 23.44% |
| Operating Income | 14.09% | 26.15% | 29.96% | 18.67% | 17.80% |
| Income Before Tax | 17.55% | 28.76% | 31.31% | 19.21% | 17.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.55% | 28.76% | 31.31% | 19.21% | 17.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.55% | 28.76% | 31.31% | 19.21% | 17.66% |
| EBIT | 14.09% | 26.15% | 29.96% | 18.67% | 17.80% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 85.16% | 87.63% | 84.64% | 59.40% | 42.96% |
| Normalized Basic EPS | 85.16% | 87.63% | 84.64% | 59.40% | 42.96% |
| EPS Diluted | 85.16% | 87.63% | 84.64% | 59.40% | 42.96% |
| Normalized Diluted EPS | 85.16% | 87.63% | 84.64% | 59.40% | 42.96% |
| Average Basic Shares Outstanding | 272.62% | 451.76% | 527.73% | 240.88% | 140.26% |
| Average Diluted Shares Outstanding | 272.62% | 451.76% | 527.73% | 240.88% | 140.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |